CUVITRU

This brand name is authorized in United States. It is also authorized in Austria, Brazil, France, Hong Kong SAR China, Ireland, Netherlands, Poland, Turkey, UK.

Active ingredients

The drug CUVITRU contains one active pharmaceutical ingredient (API):

1	Human normal immunoglobulin G UNII 66Y330CJHS - HUMAN IMMUNOGLOBULIN G
	Human normal immunoglobulin contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents. Human normal immunoglobulin contains the IgG antibodies present in the normal population. It is usually prepared from pooled plasma from not fewer than 1000 donors.
	Read more about Human normal immunoglobulin G

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CUVITRU Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J06BA01	Immunoglobulins, normal human, for extravascular adm.	J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BA Immunoglobulins, normal human
Discover more medicines within J06BA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	540219070004407, 540219070004507, 540219070004607, 540219070004707
FR	Base de données publique des médicaments	63172629
GB	Medicines & Healthcare Products Regulatory Agency	346903, 346905, 346907, 346910, 394862
HK	Department of Health Drug Office	67044
NL	Z-Index G-Standaard, PRK	139246, 201510, 97381, 97403, 97411
PL	Rejestru Produktów Leczniczych	100376653
TR	İlaç ve Tıbbi Cihaz Kurumu	8681429550394, 8681429550400, 8681429550417, 8681429550424
US	FDA, National Drug Code	0944-2850